ClinConnect ClinConnect Logo

Main Menu

Search for Trials
For HCPs
For Industry
Blog
Contact Us
Dark Mode
Log in Sign up
Search / Trial NCT00560651

German Corneal Cross Linking Register

Launched by SUPHI TANERI · Nov 19, 2007

Download PDF Apply for Trial

Trial Information

Current as of April 25, 2025

Active, not recruiting

Keywords

Keratoconus Cornea Cross Linking Uv Light Riboflavin

ClinConnect Summary

**Summary of the German Corneal Cross Linking Register Clinical Trial**

This clinical trial is studying a treatment called Corneal Cross Linking for people with a condition known as keratoconus. Keratoconus causes the cornea, which is the clear front part of the eye, to become thin and bulge outward. This can lead to serious vision problems and might require a corneal transplant if it gets worse. The goal of Corneal Cross Linking is to make the cornea stronger, stop it from bulging more, and help avoid the need for a transplant.

If you have been diagnosed with keratoconus and are being treated with Corneal Cross Linking in Germany, you might be eligible to participate in this study. The trial is currently looking for patients of all ages and genders. Participants will have their treatment recorded to help researchers understand how well it works over time and to identify any rare side effects. If you join, you can expect to receive riboflavin eye drops followed by UV light treatment, both of which are part of the Corneal Cross Linking process. Your involvement will contribute to important research that may help many others with this condition in the future.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • • Patients diagnosed with keratokonus and treated with corneal cross Linking in Germany
  • Exclusion Criteria:
  • • Non-ectatic conditions

Trial Officials

Suphi Taneri, MD

Study Chair

Augenklinik am St. Franziskus Hospital

Berthold Seitz, MD

Study Director

University of Homburg, Saar, Germany

Philip Maier, MD

Study Director

Univer. Freiburg, Germany

Claus Cursiefen, MD

Study Director

Univer. Erlangen, Germany

Thomas Reinhard, MD

Principal Investigator

Univers. Freiburg

Arnd Heiligenhaus, MD

Principal Investigator

Augenklinik am St.Franzsikus Hospital, Münster

Walter Sekundo, MD

Principal Investigator

Univers. Mainz

Theo Seiler, MD

Principal Investigator

IROC, Zürich

Atilla Osvald, MD

Principal Investigator

Univers Homurg, Saar

Jan M Vetter, MD

Principal Investigator

Univers. Mainz

About Suphi Taneri

Suphi Taneri is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative therapeutic solutions. With a focus on integrity and scientific excellence, the organization collaborates with leading research institutions and healthcare professionals to design and implement rigorous clinical trials across various therapeutic areas. Suphi Taneri prioritizes patient safety and ethical standards, ensuring that all trials are conducted in accordance with regulatory guidelines. Through its strategic approach and commitment to quality, Suphi Taneri aims to contribute significantly to the development of groundbreaking treatments and enhance the understanding of complex medical conditions.

Locations

Homburg, , Germany

Münster, , Germany

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials